Effect of opicapone multiple-dose regimens on levodopa pharmacokinetics

• Type: Article in International Scientific Journal
• Date: 2017

Authors

Rocha, JF (Author) Other; Sicard, E (Author) Other; Fauchoux, N (Author) Other; Falcao, A (Author) Other; Santos, A (Author) Other; Loureiro, AI (Author) Other; Pinto, R (Author) FMUP; Bonifacio, MJ (Author) Other; Nunes, T (Author) Other; Almeida, L (Author) Other; Soares da Silva, P (Author) Other

Journal

Title: British Journal of Clinical Pharmacology

Vol. 83

Pages: 540-553

ISSN: 0306-5251

Publisher: Wiley-Blackwell

Indexing

ISI Web of Knowledge - 13 Citations

Scopus - 14 Citations

Other information

Authenticus ID: P-00M-75N

DOI: 10.1111/bcp.13156

Abstract (EN): AIMS To compare the levodopa/carbidopa (LC) and levodopa/benserazide (LB) pharmacokinetic profiles following repeated doses of opicapone (OPC) administered apart from levodopa. METHODS Two randomized, double blind, sex-balanced, placebo-controlled studies in four groups of 12 or 18 healthy subjects each. In each group, enrolled subjects received a once-dailymorning (5, 15 and 30mg) or evening (5, 15 and 50mg) administration of OPC or placebo for up to 28 days. On the morning of Day 11, 12 h after the OPC or placebo evening dose, or the morning of Day 21, 1 h after the OPC or placebo dose, a single dose of immediate-release 100/25mg LC was administered. Similarly, on Day 18morning, 12 h after the OPC or placebo evening dose, or Day 28 morning, 1 h after the OPC or placebo dose, a single dose of immediate-release 100/ 25 mg LB was administered. RESULTS All OPC treatments, in relation to the placebo group, presented a higher extent of exposure (AUC) to levodopa following either LC or LB doses. A relevant but not dose-dependent increase in the levodopa AUC occurred with all OPC dose groups in relation to placebo. All active treatments significantly inhibited both peak (E-max) and extent (AUEC) of the catechol-O-methyltransferase activity in relation to placebo. The tolerability profile was favourable. CONCLUSION Opicapone, as once-daily oral evening regimen and/or 1 h apart from levodopa therapy, increases the bioavailability of levodopa associated with its pronounced, long-lasting and sustained catechol-O-methyltransferase inhibition. The tolerability profile was favourable and similar between OPC and placebo.

Language: English

Type (Professor's evaluation): Scientific

No. of pages: 14